AACR 2020:MET新药Bozitinib用于NSCLC,疾病控制率90%

2020-04-29 seacat 肺腾助手

Bozitinib是一种新型的MET靶向药,AACR虚拟大会报道了Bozitinib的I期临床研究数据。

Bozitinib是一种新型的MET靶向药,AACR虚拟大会报道了Bozitinib的I期临床研究数据。

研究纳入37例患者,其中11例MET 外显子14 跳跃突变,8例MET扩增、8例过表达,10例患者有1种以上MET变异。患者先前都未接受过MET或HGF靶向治疗。

研究确定Bozitinib的II期临床研究推荐剂量为200mg,每天2次口服。

患者总体的客观缓解率30.6%,疾病控制率97.2%,其中MET过表达、MET扩增和MET外显子14跳跃突变的客观缓解率,分别为35.7%、41.2%和66.7%。接受200mg,每天2次剂量的11例患者客观缓解率达72.7%,疾病控制率100%。

图六 Bozitinib的疗效

Bozitinib的耐受性总体良好。在35例患者中观察到了任何级别的与治疗相关的不良反应,在10例患者中观察到了≥3级的不良反应,包括ALT升高,AST升高,胆红素升高和周围性水肿。超过20%的患者发生的常见不良反应包括:ALT增加(40.5%),AST增加(40.5%),胆红素增加(40.5%),外周水肿(32.4%)和QTc间隔延长(18.9%)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-09-30 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2021-02-08 qingyan7590

    MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2021-02-08 qingyan7590

    塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-07-16 tamgche
  5. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-05-01 10518094zz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-05-01 Luyuxie_14
  7. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1896647, encodeId=cd38189664e0b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 30 17:57:08 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923633, encodeId=34c092363337, content=MET的还有卡马替尼,特伯替尼,沃利替尼,梅沙替尼。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:09 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923634, encodeId=df2a9236346a, content=塞尔帕替尼LOXO-292,TAS6417,布格替尼, TAK788,阿培利斯BYL-719,奥希替尼9291, 波齐替尼,卡博替尼,AZD3759,奥拉帕尼,劳拉替尼,卡帕替尼INC280, 达克替尼,甲磺酸乐伐替尼,恩曲替尼RXDX-101,拉罗替尼loxo101,阿法替尼Q426407382, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59e35459527, createdName=qingyan7590, createdTime=Mon Feb 08 11:25:27 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1665, encryptionId=f1b41665ac, topicName=AACR 2020)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Jul 16 08:57:08 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602772, encodeId=b1ad1602e72cb, content=<a href='/topic/show?id=080336333c' target=_blank style='color:#2F92EE;'>#Bozitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3633, encryptionId=080336333c, topicName=Bozitinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=506818916384, createdName=zz12341240, createdTime=Fri May 01 02:57:08 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039768, encodeId=3a3c1039e6871, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Apr 29 14:57:08 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-04-29 肿肿

    NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了

    0

相关资讯

AACR 2020:KRAS新药用于NSCLC结果公布

CH5126766 / VS-6766(简称CH)是一种试验性RAF-MEK抑制剂,defactinib是一种FAK抑制剂

AACR 2020:PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌,未获成功

IMbassador250 III研究纳入了阿比特龙治疗失败的晚期去势抵抗性前列腺癌患者,随机分为PDL1单抗Tecentriq +恩杂鲁胺组或恩杂鲁胺组。

AACR 2020:基因治疗肾细胞癌获突破,DCR可达75%!

溶瘤病毒用于肿瘤治疗被寄予厚望,作为下一代的基因疗法的主要手段。虽然它还有很多缺点,如瘤内给药的操作不够便捷、易产生中和抗体无法实现系统给药、单药使用应答率不高。而且第一个溶瘤病毒T-vec的获批上市

AACR 2020:肝内胆管癌的FGFR2一个新型突变被发现

胆道癌包括肝内胆管癌(IHCC),肝外胆管癌(EHCC)和胆囊癌(GBC)。这些癌症在临床,病理和生物学上都具有异质性,而且都具有侵袭性,预后差,可用的治疗方法也很少。迄今为止发现的潜在可操作的基因组

AACR 2020:蔡红兵教授分享COVID-19疫情癌症患者的数据

在全球新冠疫情的严峻形势下,美国癌症研究协会(AACR)2020年度会议以线上形式,于美国东部时间4月28日(周二)上午9点召开。此次会议上,来自武汉大学中南医院的蔡红兵教授接受特邀进行了主题发言,分

AACR 2020:EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%

Mobocertinib(TAK-788,曾用代号AP32788)是武田制药研发的一款小分子EGFR/HER2抑制剂,日前美国FDA已授予突破性疗法认定(BTD)药物资格。2020年4月28日,AAC

拓展阅读

AACR重磅:局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估

TTX-030、布加利单抗和FOLFOX的组合作为1L治疗LA/M胃/GEJ癌,无论CPS状态如何,都表现出良好的疗效

AACR重磅之KEYNOTE-042:帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

一线帕博丽珠单抗继续延长了中国晚期/转移性PD-L1阳性NSCLC患者的OS,并在随访近4年后提供了持久的反应。

AACR重磅:高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物

TMB和HA的组合对用替雷利珠单抗治疗各种实体瘤类型的临床获益有预测作用。

AACR重磅之RATIONALE-304:肿瘤突变负荷(TMB)与替雷利珠单抗(TIS)+化疗(chemo)与单独化疗在晚期非鳞状非小细胞肺癌(nsq-NSCLC)一线治疗的临床结局研究

tTMB和bTMB都没有与PFS获益显著相关,表明在TIS+化疗作为晚期nsq-NSCLC一线治疗的情况下,tTMB和bTMB的临床效用有限。